Vol 27, No 5 (2020)
Editorial
Published online: 2020-11-06
Cardiac injury is independently associated with mortality irrespective of comorbidity in hospitalized patients with coronavirus disease 2019
Abstract
Not available
References
- Nishiga M, Wang DW, Han Y, et al. COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. Nat Rev Cardiol. 2020; 17(9): 543–558.
- Wei ZY, Geng YJ, Huang Ji, et al. Pathogenesis and management of myocardial injury in coronavirus disease 2019. Eur J Heart Fail. 2020 [Epub ahead of print].
- Guan Wj, Liang Wh, Zhao Yi, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Resp J. 2020; 55(5): 2000547.
- Lorente-Ros A, Monteagudo Ruiz JM, Rincón LM, et al. Myocardial injury determination improves risk stratification and predicts mortality in COVID-19 patients. Cardiol J. 2020 [Epub ahead of print].
- Thygesen K, Alpert JS, Jaffe AS, et al. Fourth Universal Definition of Myocardial Infarction (2018). J Am Coll Cardiol. 2018; 72(18): 2231–2264.
- Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395(10229): 1054–1062.
- Shi S, Qin Mu, Shen Bo, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020; 5(7): 802–810.
- Nie SF, Yu M, Xie T, et al. Cardiac troponin I is an independent predictor for mortality in hospitalized patients with COVID-19. Circulation. 2020; 142(6): 608–610.
- Cao J, Zheng Y, Luo Z, et al. Myocardial injury and COVID-19: Serum hs-cTnI level in risk stratification and the prediction of 30-day fatality in COVID-19 patients with no prior cardiovascular disease. Theranostics. 2020; 10(21): 9663–9673.
- Chapman AR, Bularga A, Mills NL. High-Sensitivity cardiac troponin can be an ally in the fight against COVID-19. Circulation. 2020; 141(22): 1733–1735.
- Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020; 395(10236): 1569–1578.
- National Health Commission of the People’s Republic of China. Chinese management guideline for COVID-19 (version 8.0). August 19, 2020. http://www.nhc.gov.cn/yzygj/s7653p/202008/0a7bdf12bd4b46e5bd28ca7f9a7f5e5a/files/a449a3e2e2c94d9a856d5faea2ff0f94.pdf (accessed Aug 19, 2020; in Chinese).
